Literature DB >> 12777339

Older community residents with depression: long-term treatment with sertraline. Randomised, double-blind, placebo-controlled study.

K C M Wilson1, P G Mottram, L Ashworth, M T Abou-Saleh.   

Abstract

BACKGROUND: Despite a growing use of selective serotonin reuptake inhibitors in older people, only one trial has examined their prophylactic efficacy in people aged 65 years and over. AIMS: To examine the efficacy of sertraline in preventing the recurrence of depression in older people living in the community.
METHOD: Participants were openly treated with sertraline and then randomised into a double-blind, placebo-controlled continuation/maintenance study of about 2 years duration. Drug dosage was maintained at levels that achieved remission.
RESULTS: No significant difference between the sertraline and placebo groups was found in the proportion of recurrences (-7.9%; 95% CI -28.06 to 12.23). Increased age and minor residual symptoms during the continuation phase were associated with recurrence.
CONCLUSIONS: Sertraline at therapeutic dosage does not provide significant protection against recurrence.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12777339     DOI: 10.1192/bjp.182.6.492

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  14 in total

1.  Pharmacotherapy for late-life depression.

Authors:  George S Alexopoulos
Journal:  J Clin Psychiatry       Date:  2011-01       Impact factor: 4.384

Review 2.  Use of antidepressants in late-life depression.

Authors:  Tarek K Rajji; Benoit H Mulsant; Francis E Lotrich; Cynthia Lokker; Charles F Reynolds
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 3.  Major depressive disorder in older adults: benefits and hazards of prolonged treatment.

Authors:  Breno S Diniz; Charles F Reynolds
Journal:  Drugs Aging       Date:  2014-09       Impact factor: 3.923

Review 4.  Depression in adults: drug and physical treatments.

Authors:  Andrea Cipriani; Corrado Barbui; Rob Butler; Simon Hatcher; John Geddes
Journal:  BMJ Clin Evid       Date:  2011-05-25

Review 5.  Studies of long-term use of antidepressants: how should the data from them be interpreted?

Authors:  Rif S El-Mallakh; Brian Briscoe
Journal:  CNS Drugs       Date:  2012-02-01       Impact factor: 5.749

Review 6.  Continuation treatment of major depressive disorder: is there a case for duloxetine?

Authors:  Trevor R Norman; James S Olver
Journal:  Drug Des Devel Ther       Date:  2010-02-18       Impact factor: 4.162

Review 7.  Getting better, getting well: understanding and managing partial and non-response to pharmacological treatment of non-psychotic major depression in old age.

Authors:  Henry C Driscoll; Jordan F Karp; Mary Amanda Dew; Charles F Reynolds
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 8.  Depression in adults: drug and physical treatments.

Authors:  Corrado Barbui; Rob Butler; Andrea Cipriani; John Geddes; Simon Hatcher
Journal:  BMJ Clin Evid       Date:  2007-06-15

9.  Assessing rates and predictors of tachyphylaxis during the prevention of recurrent episodes of depression with venlafaxine ER for two years (PREVENT) study.

Authors:  Anthony J Rothschild; Boadie W Dunlop; David L Dunner; Edward S Friedman; Alan Gelenberg; Peter Holland; James H Kocsis; Susan G Kornstein; Richard Shelton; Madhukar H Trivedi; John M Zajecka; Corey Goldstein; Michael E Thase; Ron Pedersen; Martin B Keller
Journal:  Psychopharmacol Bull       Date:  2009

10.  Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults.

Authors:  Ellen Van Leeuwen; Mieke L van Driel; Mark A Horowitz; Tony Kendrick; Maria Donald; An Im De Sutter; Lindsay Robertson; Thierry Christiaens
Journal:  Cochrane Database Syst Rev       Date:  2021-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.